Group 1 - The clinical trial for Amoxicillin capsules by Zhejiang Anglikang Pharmaceutical Co., Ltd. has been initiated, focusing on the bioequivalence study in healthy Chinese subjects [1] - The trial is designed as a single-center, open-label, randomized, single-dose, two-period, two-sequence, and crossover study, with a clinical trial registration number of CTR20255192 [1] - The primary objective is to evaluate the pharmacokinetics of the test formulation compared to the reference formulation under fasting conditions, while the secondary objective assesses the safety of both formulations [1] Group 2 - The trial's primary endpoints include Cmax, AUC0-t, AUC0-∞, vital signs, physical examinations, 12-lead ECG, clinical laboratory tests, and adverse events, evaluated 12 hours post-administration [2] - Secondary endpoints consist of Tmax, t1/2, λz, AUC_%Extrap, Vd/F, CL/F, F, along with the same safety assessments as primary endpoints, evaluated until the end of follow-up [2] - The current status of the trial is ongoing, with a target enrollment of 24 participants [3]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the promising data from CTLA-4 drugs, suggesting potential investment opportunities in related areas [3][5] - The pharmaceutical index experienced a slight decline of 0.14% from December 15 to December 19, 2025, but showed a relative outperformance of 0.14% against the CSI 300 index [5] - The report emphasizes the importance of innovative drugs as a key investment theme for 2026, with a focus on companies that are expected to show clear performance trends and potential reversals in operations [5][41] Summary by Sections 1. CTLA-4 Target - CTLA-4 is identified as a significant immune checkpoint that can inhibit T cell activation, presenting potential value in cancer immunotherapy [8][9] - The CTLA-4 monoclonal antibody Gotistobart shows promising clinical trial results for squamous non-small cell lung cancer (sqNSCLC) patients who are resistant to immunotherapy [14][15] - Gotistobart's innovative mechanism targets Treg cells in the tumor microenvironment, potentially leading to a new paradigm in tumor immunotherapy [20][24] 2. Industry Perspective - The report maintains that innovative drugs should be the main focus for the year, while also considering manufacturing exports and aging-related consumption as relatively undervalued assets [25][41] - The pharmaceutical index has shown a year-to-date increase of 14.49%, with a notable number of stocks experiencing significant gains [25][26] - The report suggests that the Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs opening new growth avenues for companies [41][42] 3. Investment Recommendations - Recommended stocks include innovative drug companies such as Xinyi Tai, Zai Jian Pharmaceutical, and others, as well as companies in the medical device sector [5][45] - The report advises focusing on companies with strong performance trends and those expected to benefit from the aging population and outpatient consumption [42][44] - The report also highlights the potential of AI in the pharmaceutical sector, suggesting that related stocks may perform well in the coming years [42][44]

Group 1 - The company held its third extraordinary general meeting of shareholders on December 16, 2025, to discuss significant matters, including the issuance of A-shares to specific targets [3][4][6] - The meeting was attended by 404 shareholders and representatives, representing 50.0819% of the total voting shares [5] - The company ensured that the voting process included separate counting for minority investors to enhance their participation [2] Group 2 - The proposal for the issuance of A-shares was approved with 99.6421% of the votes in favor, indicating strong support from shareholders [6] - The company plans to issue A-shares to specific targets, with the total number of shares and pricing principles also approved during the meeting [7][11][12] - The total expected amount for daily related transactions for 2025 was increased to RMB 16.55 million, reflecting adjustments based on operational needs [28][29] Group 3 - The company confirmed that the adjustments to related transactions do not exceed 0.5% of the latest audited net assets, thus falling within the general manager's decision-making authority [30] - The company maintains that the related transactions are conducted at market prices and are essential for normal business operations, ensuring no adverse impact on financial conditions [33]

Core Viewpoint - The company announced an increase in the expected amount of related party transactions due to operational needs with Baiyunshan Anglikang, with the procurement amount for electricity rising from 380,000 to 450,000 yuan by 2025 [1] Group 1 - The expected annual related party transaction amount for 2025 is adjusted to not exceed 16.55 million yuan (excluding tax) [1] - The procurement amount for its subsidiary, Animal Health Technology, remains unchanged, and transactions with other related parties are also unaffected [1] - The increase in transaction amount does not exceed 0.5% of the company's most recent audited net assets, thus falling within the general manager's decision-making authority without requiring board or shareholder approval [1]

证券代码：002940 证券简称：昂利康 公告编号：2025-104 浙江昂利康制药股份有限公司 关于增加 2025 年度日常关联交易预计额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江昂利康制药股份有限公司（以下简称"公司"或"昂利康"）于 2025 年 12 月 16 日召开经营管理层会议，同意公司增加 2025 年度日常关联交易预计 额度，现将具体情况公告如下： 一、日常关联交易基本情况 现由于公司与关联方浙江白云山昂利康制药股份有限公司（以下简称"白云 山昂利康"）经营活动需要，拟增加关联交易预计额度。公司原预计 2025 年公司 子公司浙江昂利康动保科技有限公司（以下简称"动保科技"）向白云山昂利康 采购商品即采购电的预计金额为 36 万元（不含税），公司向白云山昂利康采购商 品即采购电的关联交易预计金额为 2 万元（不含税），现根据实际经营情况，拟 增加关联交易预计额度。公司拟增加向白云山昂利康采购商品的关联交易预计额 度，即原预计公司 2025 年向白云山昂利康采购商品即采购电的金额由 2 万元增 1 加至 9 万元，不调整动保科 ...

2025 年第三次临时股东会的 浙江天册律师事务所 法律意见书 关于浙江昂利康制药股份有限公司 本法律意见书仅供昂利康 2025 年第三次临时股东会之目的使用。本所律师同意将 本法律意见书随昂利康本次股东会其他信息披露资料一并公告。 根据昂利康公告的《浙江昂利康制药股份有限公司关于召开 2025 年第三次临时股 东会的通知》（以下统称"会议通知"），提请本次股东会审议的事项为： 法律意见书 编号：TCYJS2025H2163 致：浙江昂利康制药股份有限公司 根据《中华人民共和国证券法》（下称"《证券法》"）、《中华人民共和国公司 法》（下称"《公司法》"）和《上市公司股东会规则》等法律、法规和规范性文件的 要求及《浙江昂利康制药股份有限公司章程》（下称"《公司章程》"）、《浙江昂利 康制药股份有限公司股东会议事规则》（下称"《议事规则》"）的规定，浙江天册律 师事务所（下称"本所"）接受浙江昂利康制药股份有限公司（下称"昂利康"或"公 司"）的委托，指派俞晓瑜、吴钰颖律师（下称"本所律师"）参加昂利康 2025 年第 三次临时股东会，对本次股东会的召集和召开程序、出席会议人员资格、表决方式、表 决程序的合法性 ...

证券代码：002940 证券简称：昂利康 公告编号：2025-103 浙江昂利康制药股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示 1、为尊重中小投资者利益，提高中小投资者对公司股东会审议的重大事项 参与度，本次股东会审议的部分议案对中小投资者实行单独计票。中小投资者是 指除以下股东以外的其他股东：（1）上市公司的董事、高级管理人员；（2）单独 或者合计持有上市公司 5%以上股份的股东； 2、本次股东会无否决或修改议案情况； 3、本次股东会没有涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 现场会议召开时间：2025 年 12 月 16 日下午 14：00 网络投票时间：2025 年 12 月 16 日 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 12 月 16 日上午 9：15 至 9：25，9：30 至 11：30 和下午 13：00 至 15：00； 4、会议召开方式：本次会议采取现场投票和网络投票相结合的方式 5、会 ...

证券日报网讯12月15日晚间，昂利康（002940）发布公告称，浙江昂利康制药股份有限公司子公司浙江 昂利康医药销售有限公司于2025年12月12日以现金方式收到一笔与收益相关的政府补助资金1，047.1万 元。 ...

每经AI快讯，昂利康（SZ 002940，收盘价：32.96元）12月15日晚间发布公告称，浙江昂利康制药股份 有限公司子公司浙江昂利康医药销售有限公司于2025年12月12日以现金方式收到一笔与收益相关的政府 补助资金1047.1万元，占公司最近一期经审计的归属于上市公司股东净利润的13.03%。 截至发稿，昂利康市值为66亿元。 每经头条（nbdtoutiao）——"一针两千，童颜针年销3亿元"背后：多家关联方注册地"查无此人"，股民 追问"钱呢"！钱氏姐弟几乎"掏空"江苏吴中，公司即将退市 （记者 曾健辉） 2025年1至6月份，昂利康的营业收入构成为：医药制造业占比100.0%。 ...

格隆汇12月15日丨昂利康(002940.SZ)公布，公司子公司浙江昂利康医药销售有限公司于2025年12月12 日以现金方式收到一笔与收益相关的政府补助资金1047.1万元，占公司最近一期经审计的归属于上市公 司股东净利润的13.03%。 ...